SI2627334T1 - Sestavki za uporabo pri zdravljenju virusnih infekcij - Google Patents

Sestavki za uporabo pri zdravljenju virusnih infekcij

Info

Publication number
SI2627334T1
SI2627334T1 SI201130489T SI201130489T SI2627334T1 SI 2627334 T1 SI2627334 T1 SI 2627334T1 SI 201130489 T SI201130489 T SI 201130489T SI 201130489 T SI201130489 T SI 201130489T SI 2627334 T1 SI2627334 T1 SI 2627334T1
Authority
SI
Slovenia
Prior art keywords
compositions
treatment
viral infections
infections
viral
Prior art date
Application number
SI201130489T
Other languages
English (en)
Slovenian (sl)
Inventor
Shanta Bantia
Pravin L. Kotian
Yarlagadda S. Babu
Original Assignee
Biocryst Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharmaceuticals, Inc. filed Critical Biocryst Pharmaceuticals, Inc.
Publication of SI2627334T1 publication Critical patent/SI2627334T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06—Heterocyclic radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI201130489T 2010-10-15 2011-10-14 Sestavki za uporabo pri zdravljenju virusnih infekcij SI2627334T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39352210P 2010-10-15 2010-10-15
US201161492054P 2011-06-01 2011-06-01
PCT/US2011/056421 WO2012051570A1 (en) 2010-10-15 2011-10-14 Methods and compositions for inhibition of polymerase
EP11833515.7A EP2627334B1 (en) 2010-10-15 2011-10-14 Compositions for use in the treatment of viral infections

Publications (1)

Publication Number Publication Date
SI2627334T1 true SI2627334T1 (sl) 2015-08-31

Family

ID=45938737

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201130489T SI2627334T1 (sl) 2010-10-15 2011-10-14 Sestavki za uporabo pri zdravljenju virusnih infekcij
SI201131383T SI2898885T1 (en) 2010-10-15 2011-10-14 Pyrrolopyrimidine derivatives for use in the treatment of viral infections

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI201131383T SI2898885T1 (en) 2010-10-15 2011-10-14 Pyrrolopyrimidine derivatives for use in the treatment of viral infections

Country Status (23)

Country Link
US (5) US20130331404A1 (enExample)
EP (3) EP3345605B1 (enExample)
JP (2) JP5902698B2 (enExample)
KR (1) KR101850925B1 (enExample)
CN (1) CN103429245B (enExample)
AU (2) AU2011315902B2 (enExample)
BR (1) BR112013009029B1 (enExample)
CA (1) CA2813783C (enExample)
CY (1) CY1119880T1 (enExample)
DK (2) DK2627334T3 (enExample)
ES (2) ES2657687T3 (enExample)
HR (2) HRP20150487T1 (enExample)
HU (1) HUE036387T2 (enExample)
IL (1) IL225672B (enExample)
LT (1) LT2898885T (enExample)
MX (1) MX348759B (enExample)
PL (2) PL2898885T3 (enExample)
PT (2) PT2898885T (enExample)
RS (2) RS56870B1 (enExample)
RU (3) RU2599013C2 (enExample)
SI (2) SI2627334T1 (enExample)
SM (2) SMT201800064T1 (enExample)
WO (1) WO2012051570A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE038946T2 (hu) 2008-04-23 2018-12-28 Gilead Sciences Inc 1'-szubsztituált carba-nukleozid analógok antivirális kezelésre
JP5767643B2 (ja) 2009-09-21 2015-08-19 ギリード・サイエンシズ・インコーポレーテッド １’−置換カルバヌクレオシド類似体の調製のためのプロセスおよび中間体
KR101995598B1 (ko) 2010-07-19 2019-07-02 길리애드 사이언시즈, 인코포레이티드 부분입체 이성질성으로 순수한 포스포라미데이트 전구약물의 제조 방법
PE20130400A1 (es) 2010-07-22 2013-04-10 Gilead Sciences Inc Metodos y compuestos para tratar infecciones virales por paramyxoviridae
RS56870B1 (sr) 2010-10-15 2018-04-30 Biocryst Pharm Inc Pirolopirimidinski derivati za primenu u lečenju virusnih infekcija
AR090699A1 (es) * 2012-04-18 2014-12-03 Biocryst Pharm Inc Compuestos inhibidores de la actividad de la arn polimerasa viral
HK1212235A1 (en) * 2012-11-16 2016-06-10 Biocryst Pharmaceuticals, Inc. Antiviral azasugar-containing nucleosides
US9499554B2 (en) 2013-05-14 2016-11-22 Biocryst Pharmaceuticals, Inc. Anti-influenza compositions and methods
TWI678369B (zh) * 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類
TWI698444B (zh) 2014-10-29 2020-07-11 美商基利科學股份有限公司 製備核糖苷的方法
CN104513249B (zh) * 2014-12-26 2016-08-31 苏州明锐医药科技有限公司 抗埃博拉病毒药物bcx4430的制备方法
PT3349758T (pt) 2015-09-16 2022-07-13 Gilead Sciences Inc Métodos para o tratamento de infeções pelo vírus arenaviridae
WO2017155886A1 (en) * 2016-03-06 2017-09-14 Biocryst Pharmaceuticals, Inc. Methods and compositions for treatment of zika virus infection
DE102016002873A1 (de) 2016-03-09 2016-05-25 Heinz Kiefer Zellnachweisverfahren und Screeningverfahren von Stoffbibliotheken zur Identifizierung von Einzelstoffen, die im Falle einer bioterroristischen Bedrohung gegen Mischungen synthetischer Viren wirksam sind
CN110869028B (zh) 2017-03-14 2023-01-20 吉利德科学公司 治疗猫冠状病毒感染的方法
KR20190141747A (ko) 2017-05-01 2019-12-24 길리애드 사이언시즈, 인코포레이티드 (S)-2-에틸부틸 2-(((S)-(((2R,3S,4R,5R)-5-(4-아미노피롤로[2,1-f] [1,2,4]트리아진-7-일)-5-시아노-3,4-디히드록시테트라히드로푸란-2-일)메톡시)(페녹시) 포스포릴)아미노)프로파노에이트의 결정질 형태
US10675296B2 (en) 2017-07-11 2020-06-09 Gilead Sciences, Inc. Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
US20220273689A1 (en) * 2019-07-09 2022-09-01 Regents Of The University Of Minnesota Potentiation of antiviral nucleobases as rna virus therapy
CN118766947A (zh) 2020-01-27 2024-10-15 吉利德科学公司 用于治疗SARS CoV-2感染的方法
CA3169340A1 (en) 2020-03-12 2021-09-16 Pavel R. Badalov Methods of preparing 1'-cyano nucleosides
JP7482250B2 (ja) 2020-04-06 2024-05-13 ギリアード サイエンシーズ， インコーポレイテッド １’－シアノ置換カルバヌクレオシド類似体の吸入製剤
WO2021207386A1 (en) * 2020-04-07 2021-10-14 Biocryst Pharmaceuticals, Inc. Methods, compositions, and dosing regimens for treatment of sars-cov-2 infections
PL4157272T3 (pl) 2020-05-29 2025-10-20 Gilead Sciences, Inc. Remdesiwir do leczenia zakażeń wirusowych
JP2023531524A (ja) 2020-06-24 2023-07-24 ギリアード サイエンシーズ， インコーポレイテッド １’－シアノヌクレオシド類似体及びその使用
LT4204421T (lt) 2020-08-27 2024-06-25 Gilead Sciences, Inc. Virusinių infekcijų gydymui skirti junginiai ir būdai
KR102871928B1 (ko) * 2021-06-25 2025-10-20 전남대학교 산학협력단 지방분해효소 억제제를 포함하는 rna 바이러스 감염증 예방 또는 치료용 약제학적 조성물
EP4360629A4 (en) * 2021-06-25 2024-11-06 Industry Foundation of Chonnam National University PHARMACEUTICAL COMPOSITION COMPRISING A LIPASE INHIBITOR FOR THE TREATMENT OF RNA VIRAL INFECTIONS
WO2023023469A1 (en) * 2021-08-17 2023-02-23 Southwest Research Institute Inhibitors for coronavirus
CN115925640B (zh) * 2021-08-23 2025-03-28 中国人民解放军军事科学院军事医学研究院 ((3-氨甲酰-5-氟吡嗪-2-基)氧基)甲基异丁酸酯及其制备方法和应用
US20230295172A1 (en) 2022-03-02 2023-09-21 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
CN118359622B (zh) * 2024-04-16 2025-08-26 上海陶术生物科技股份有限公司 加利司伟中间体的制备方法
CN118359621B (zh) * 2024-04-16 2025-05-16 上海陶术生物科技股份有限公司 加利司伟及加利司伟中间体的制备方法和相应的加利司伟中间体

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9520364D0 (en) * 1995-10-05 1995-12-06 Chiroscience Ltd Compouundds
US5985848A (en) 1997-10-14 1999-11-16 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside metabolism
US6228741B1 (en) 1998-01-13 2001-05-08 Texas Instruments Incorporated Method for trench isolation of semiconductor devices
US7388002B2 (en) 2001-11-14 2008-06-17 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
US7098334B2 (en) * 2002-03-25 2006-08-29 Industrial Research Limited 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases
WO2003100009A2 (en) * 2002-05-23 2003-12-04 Biocryst Pharmaceuticals, Inc. Enhancing the efficacy of reverse transcriptase and dna polymerase inhibitors (nucleoside analogs) using pnp inhibitors and/or 2'-deoxyguanosine and/or prodrug thereof
WO2006002231A1 (en) * 2004-06-22 2006-01-05 Biocryst Pharmaceuticals, Inc. Aza nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
EP2537520A1 (en) 2005-03-29 2012-12-26 Biocryst Pharmaceuticals, Inc. Hepatics C therapies
US20090227637A1 (en) * 2005-12-15 2009-09-10 Olaf Weber Diaryl ureas for treating virus infections
NZ575365A (en) 2006-09-07 2012-02-24 Ind Res Ltd Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases
WO2008067002A2 (en) 2006-09-11 2008-06-05 Southern Research Institute Azole nucleosides and use as inhibitors of rna and dna varial polymerases
TW200942243A (en) 2008-03-05 2009-10-16 Biocryst Pharm Inc Antiviral therapeutic agents
RS56870B1 (sr) 2010-10-15 2018-04-30 Biocryst Pharm Inc Pirolopirimidinski derivati za primenu u lečenju virusnih infekcija
AU2011327903A1 (en) 2010-11-11 2013-05-02 Redx Pharma Plc Drug derivatives
AR090699A1 (es) * 2012-04-18 2014-12-03 Biocryst Pharm Inc Compuestos inhibidores de la actividad de la arn polimerasa viral

Also Published As

Publication number Publication date
DK2898885T3 (en) 2018-02-05
SMT201500148B (it) 2015-09-07
PT2627334E (pt) 2015-07-07
ES2536831T3 (es) 2015-05-29
US10022375B2 (en) 2018-07-17
LT2898885T (lt) 2018-02-26
AU2017200471A1 (en) 2017-02-23
RU2718690C2 (ru) 2020-04-13
MX348759B (es) 2017-06-28
EP3345605A1 (en) 2018-07-11
RU2599013C2 (ru) 2016-10-10
RU2016134401A3 (enExample) 2020-01-24
RS54072B1 (sr) 2015-10-30
RU2020111042A (ru) 2021-09-17
HRP20150487T1 (hr) 2015-08-28
EP2627334A4 (en) 2014-04-16
US20170042901A1 (en) 2017-02-16
RU2013121794A (ru) 2014-11-20
BR112013009029A2 (pt) 2018-06-19
HK1257363A1 (en) 2019-10-18
IL225672B (en) 2019-02-28
CY1119880T1 (el) 2018-06-27
MX2013003938A (es) 2013-07-05
HK1212914A1 (en) 2016-06-24
CA2813783C (en) 2019-01-22
CN103429245A (zh) 2013-12-04
JP5902698B2 (ja) 2016-04-13
IL225672A0 (en) 2013-06-27
AU2017200471B2 (en) 2018-04-12
US20150051230A1 (en) 2015-02-19
ES2657687T3 (es) 2018-03-06
BR112013009029B1 (pt) 2021-06-29
JP2013544788A (ja) 2013-12-19
SI2898885T1 (en) 2018-03-30
SMT201800064T1 (it) 2018-03-08
CA2813783A1 (en) 2012-04-19
US20130331404A1 (en) 2013-12-12
KR101850925B1 (ko) 2018-04-20
PT2898885T (pt) 2018-02-05
AU2011315902B2 (en) 2016-11-17
US11173159B2 (en) 2021-11-16
US20180360836A1 (en) 2018-12-20
RS56870B1 (sr) 2018-04-30
US9492452B2 (en) 2016-11-15
US20220040190A1 (en) 2022-02-10
EP2627334A1 (en) 2013-08-21
EP2627334B1 (en) 2015-04-29
DK2627334T3 (en) 2015-05-18
HRP20180220T1 (hr) 2018-03-09
WO2012051570A1 (en) 2012-04-19
EP2898885B1 (en) 2017-11-22
PL2627334T3 (pl) 2015-08-31
US10420769B2 (en) 2019-09-24
JP2016135790A (ja) 2016-07-28
CN103429245B (zh) 2016-10-05
KR20140040676A (ko) 2014-04-03
AU2011315902A1 (en) 2013-05-30
RU2016134401A (ru) 2018-12-10
US20190374544A1 (en) 2019-12-12
EP3345605B1 (en) 2019-11-20
PL2898885T3 (pl) 2018-04-30
HUE036387T2 (hu) 2018-07-30
EP2898885A1 (en) 2015-07-29

Similar Documents

Publication Publication Date Title
PL2627334T3 (pl) Kompozycje do stosowania w leczeniu zakażeń wirusowych
PL2667849T3 (pl) Kompozycja musująca w postaci stałej do zastosowania dopochwowego w leczeniu zakażeń pochwy
GB2478595B (en) Phytocannabinoids in the treatment of glioma
EP2646468A4 (en) ANTI-NGF COMPOSITIONS AND THEIR USE
IL232046A (en) Furein derivatives for the treatment of viral infections
ZA201500921B (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diaseases
PL2768937T3 (pl) Preparaty, ich zastosowanie jako środków do mycia naczyń lub do wytwarzania środków do mycia naczyń i ich wytwarzanie
PL2521562T3 (pl) Ev576 do zastosowania w leczeniu zakażeń wirusowych dróg oddechowych
EP2755486A4 (en) DISINFECTING COMPOSITIONS AND USES THEREOF
IL236823A0 (en) Preparations for use in the treatment of bone defects
PL2903608T3 (pl) Kompozycja farmaceutyczna obejmująca kwas propionowy do stosowania w leczeniu infekcji wirusowych
EP2668044A4 (en) COMPOSITIONS AND THEIR USE
EP2624841A4 (en) COMPOSITIONS FOR TREATING CHRONIC VIRAL INFECTIONS
PL2534302T3 (pl) Kompozycja do obróbki powierzchni
GB2515440B (en) Vesicular Formulations for use in the treatment of Rosacea
ZA201307058B (en) Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment
ZA201308025B (en) The use of secnidazole in treating dental infections
ZA201306342B (en) The treatment of viral infections
ZA201302438B (en) Pharmaceutical composition for treating hcv infections
ZA201207226B (en) Compositions and methods for treating viral diseases
LT2460509T (lt) Kompozicija, skirta karpų gydymui
PL2838903T3 (pl) Sposoby i kompozycje do leczenia zakażeń wirusowych
EP2529728A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF BACTERIAL INFECTIONS
GB201012168D0 (en) Treatment of viral infections
GB201001821D0 (en) Treatment of viral infections